Omeros Co. (NASDAQ:OMER) Receives $22.50 Consensus PT from Brokerages

Omeros Co. (NASDAQ:OMER) has been given an average recommendation of “Moderate Buy” by the five research firms that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $22.50.

Several brokerages have recently weighed in on OMER. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a report on Tuesday. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research note on Tuesday. Finally, D. Boral Capital reiterated a “buy” rating and set a $36.00 target price on shares of Omeros in a research report on Tuesday.

Institutional Trading of Omeros

A number of large investors have recently modified their holdings of OMER. Two Sigma Investments LP raised its position in Omeros by 8.8% during the 4th quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company’s stock valued at $1,610,000 after purchasing an additional 13,201 shares in the last quarter. ProShare Advisors LLC raised its holdings in shares of Omeros by 75.0% in the fourth quarter. ProShare Advisors LLC now owns 18,496 shares of the biopharmaceutical company’s stock valued at $183,000 after acquiring an additional 7,927 shares in the last quarter. Nomura Holdings Inc. lifted its stake in Omeros by 136.2% in the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock worth $7,383,000 after acquiring an additional 430,932 shares during the period. Millennium Management LLC grew its holdings in Omeros by 46.2% during the 4th quarter. Millennium Management LLC now owns 85,671 shares of the biopharmaceutical company’s stock worth $846,000 after acquiring an additional 27,088 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Omeros by 3.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 1,110 shares during the period. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Price Performance

Omeros stock opened at $7.06 on Wednesday. The firm has a market capitalization of $409.93 million, a P/E ratio of -3.06 and a beta of 2.35. Omeros has a 1-year low of $2.97 and a 1-year high of $13.60. The company’s 50-day moving average is $8.56 and its 200 day moving average is $7.63.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.